US President Donald Trump on Monday falsely accused the US Food and Drug Administration, drugmaker Pfizer and the Democrats of apparently conspiring to delay an announcement of progress on a coronavirus vaccine until after last week’s elections. Pfizer Inc. said Monday that its COVID-19 vaccine may be a remarkable 90 percent effective, based on early and incomplete test results that nevertheless brought a big burst of optimism to a world desperate for the means to finally bring the catastrophic outbreak under control. The announcement came less than a week after an election seen as a referendum on Trump’s handling of the scourge, which has killed more than 1.2 million people worldwide, including almost a quarter-million in the United States alone. Get The Times of Israel's Daily Edition by email and never miss our top stories Free Sign Up Despite cheering the news early on Monday, Trump posted a series of tweets later Monday accusing Pfizer and the US Food and Drug Administration of waiting until after the election to announce its positive vaccine news for political reasons. “As I have long said, @Pfizer and the others would only announce a Vaccine after the Election, because they didn’t have the courage to do it before. Likewise, the@US_FDA should have announced it earlier, not for political purposes, but for saving lives,” Trump tweeted. “The @US_FDAand the Democrats didn’t want to have me get a Vaccine WIN, prior to the election, so instead it came out five days later – As I’ve said all along!” he added. The @US_FDA and the Democrats didn’t want to have me get a Vaccine WIN, prior to the election, so instead it came out five days later – As I’ve said all along! — Donald J. Trump (@realDonaldTrump) November 10, 2020 Pfizer has insisted that its work is not influenced by politics and that it was “moving at the speed of science.” The company itself learned of the interim results on Sunday after its independent data monitors met to discuss them. The FDA was not involved in Pfizer’s decision to announce its early results and did not make any announcements of its own. Pfizer initially opted not to join the Trump administration’s Operation Warp Speed, which helped fund a half-dozen vaccine makers’ research and manufacturing scale-up. Pfizer instead said it has invested $2 billion of its own money in testing and expanding manufacturing capacity. But in July, Pfizer signed a contract to supply the US with 100 million doses for $1.95 billion, assuming the vaccine is cleared by the FDA. Pfizer said its only involvement in Operation Warp Speed is that those doses are part of the administration’s goal to have 300 million doses of COVID-19 vaccines ready sometime next year. “We’re in a position potentially to be able to offer some hope,” Dr. Bill Gruber, Pfizer’s senior vice president of clinical development, told The Associated Press. “We’re very encouraged.” Pfizer, which is developing the vaccine with its German partner BioNTech, now is on track to apply later this month for emergency-use approval from the FDA, once it has the necessary safety information in hand. Even if all goes well, authorities have stressed it is unlikely any vaccine will arrive much before the end of the year, and the limited initial supplies will be rationed. Dr. Anthony Fauci, the US government’s top infectious-disease expert, said the results suggesting 90% effectiveness are “just extraordinary,” adding: “Not very many people expected it would be as high as that.” “It’s going to have a major impact on everything we do with respect to COVID,” Fauci said as Pfizer appeared to take the lead in the all-out global race by pharmaceutical companies and various countries to develop a well-tested vaccine against the virus. This May 4, 2020, file photo provided by the University of Maryland School of Medicine, shows the first patient enrolled in Pfizer’s COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore (Courtesy of University of Maryland School of Medicine via AP, File) Dr. Bruce Aylward, the World Health Organization’s senior adviser, said Pfizer’s vaccine could “fundamentally change the direction of this crisis” by March, when the UN agency hopes to start vaccinating high-risk groups. Global markets, already buoyed by the victory of President-elect Joe Biden, rallied on the news from Pfizer. The S&P 500 finished the day with a gain of 1.2%, while the Dow Jones Industrial Average rose more than 800 points. Pfizer stock was up more than 8%. Still, Monday’s announcement doesn’t mean for certain that a vaccine is imminent: This interim analysis, from an independent data monitoring board, looked at 94 infections recorded so far in a study that has enrolled nearly 44,000 people in the US and five other countries. Some participants got the vaccine, while others got dummy shots. Pfizer released no specific breakdowns, but for the vaccine to be 90% effective, nearly all the infections must have occurred in placebo recipients. The study is continuing, and Pfizer cautioned that the protection rate might change as more COVID-19 cases are added to the calculations. Earlier, Trump, who had suggested repeatedly during the presidential campaign that a vaccine could be ready by Election Day, tweeted: “STOCK MARKET UP BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT NEWS!” Biden, for his part, welcomed the news but cautioned that it could be many months before vaccinations become widespread in the US, and he warned Americans to rely on masks and social distancing in the meantime. He said the country still faces a “dark winter.” A Pfizer production line for the COVID-19 vaccine (Screencapture/YouTube) Confirmed infections in the US eclipsed 10 million on Monday, the highest in the world. New cases are running at all-time highs of more than 100,000 per day. And tens of thousands more deaths are feared in the coming months, with the onset of cold weather and the holidays. Pfizer’s vaccine is among four candidates already in huge studies in the US, with still more being tested in other countries. Another US company, Moderna Inc., also hopes to file an application with the FDA late this month. Both companies’ shots are made with a brand-new technology. These “mRNA vaccines” aren’t made with the coronavirus itself, meaning there’s no chance anyone could catch it from the shots. Instead, the vaccine contains a piece of genetic code that trains the immune system to recognize the spiked protein on the surface of the virus.